Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner

Inclusion Criteria: * Subjects Age \> 18 years and ≤65 years - Male or Female * Subjects with Type 2 Diabetes \> 1 and ≤ 10 years in duration * Subjects with an Hb A1c level \> 7.5 and ≤ 10.0 * Subjects taking oral Type 2 Diabetes medications and/or insulin. Metformin is allowed, but not required. * Subjects with a BMI \> 30 and\< 50 * Subjects willing to comply with study requirements * Subjects who have signed an informed consent form * Women who are post-menopausal, surgically sterile or on contraceptives and agree to remain on contraceptives for the duration of their study participation and agree not to become pregnant during the study. Exclusion Criteria: * Subjects taking Inhibitors of dipeptidyl peptidase 4 inhibitors (ie. Januvia (sitagliptin), Galvus (vildagliptin) or incretins (ie. Byetta (exenatide), Victoza (liraglutide) * Subjects requiring insulin \>150 units per day • Subjects with probable insulin production failure (fasting C Peptide serum \<1.0 ng/mL) * Subjects diagnosed with Type 1 Diabetes Mellitus or having a history of ketoacidosis * Subjects requiring NSAIDs (non-steroidal anti-inflammatory drugs) or prescription anticoagulation therapy during the implant period * Subjects with or a history of iron deficiency and/or iron deficiency anemia * Subjects with or a history of abnormalities of the GI tract * Subjects with symptomatic gallstones or kidney stones at the time of screening * Subjects with a known infection * Subjects with or a history of coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia * Subjects mentally retarded or emotionally unstable, or exhibits psychological characteristics which, in the opinion of the Investigator, makes the subject a poor candidate for device placement or clinical study participation * Subjects with previous GI surgery that could affect the ability to place the device or the function of the implant * Subjects with active H. pylori (Note: Subjects may be enrolled if they had a prior history of H. Pylori and were successfully treated. If Subjects have active H. pylori at baseline, they can receive appropriate treatment and then subsequently enroll to the study.) * Subject or Family history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder * Subjects with active and uncontrolled gastroesophageal reflux disease (GERD) * Subjects with severe liver or kidney failure (serum creatinine \>180mmol/l) * Subjects with poor dentition who can not adequately chew their food